# Application value of gastric contrast ultrasonography in gastric tumors

**Authors:** Guanmo Liu, Jie Li, Hua Liang, Zicheng Zheng, Chenggang Zhang, Yixuan He, Yihua Wang, Yang Gui, Weiming Kang, Xin Ye

PMC · DOI: 10.1186/s13244-026-02242-3 · Insights into Imaging · 2026-03-17

## TL;DR

This review discusses how gastric contrast ultrasonography can help detect and stage gastric tumors, offering a noninvasive and accessible alternative to other methods.

## Contribution

The paper highlights the potential of gastric contrast ultrasonography and proposes strategies to improve its clinical use through standardization and AI integration.

## Key findings

- Gastric contrast ultrasonography is effective for detecting and staging gastric tumors.
- The technique is noninvasive, cost-effective, and real-time, making it suitable for screening.
- Standardization and AI integration are needed to enhance its clinical application.

## Abstract

In recent years, gastric oral contrast ultrasonography (OCUS) and double contrast-enhanced ultrasonography (DCEUS) have emerged as promising imaging techniques for evaluating gastric tumors, particularly gastric cancer (GC), by providing beneficial insights into tumor morphology, vascular characteristics and response to therapy. OCUS is capable of identifying the thickened gastric wall and lesions by utilizing oral contrast agents. DCEUS, based on OCUS, further employs intravenous contrast-enhanced ultrasound to examine regions of interest, thereby revealing both the anatomical features and perfusion characteristics of the lesions. These two methods are known for being non-irradiating, cost-effective, noninvasive and real-time. With advances in contrast agents and imaging technology, OCUS and DCEUS are expected to become increasingly reliable and contribute to improving patient prognoses. However, the clinical application of these techniques is still evolving, limited by a lack of technical standardization, operator dependence, and inadequate evaluation in certain tumor subtypes and patient populations. This review summarizes the current state in clinical practice of OCUS and DCEUS in the screening, diagnosis, staging and treatment assessment of gastric tumors. It also proposes possible orientations for clinicians to address the identified limitations and improve the clinical value of OCUS and DCEUS, including the integration of artificial intelligence and molecular imaging, alongside establishing international standardization protocols, enhancing physician training systems, and expanding accessibility to primary care settings. Through these efforts, OCUS and DCEUS may become indispensable components of future GC management strategies.

By summarizing gastric contrast ultrasonography across screening, diagnosis, T staging, N staging and treatment assessment in gastric tumors, and comparing with CT, EUS and endoscopy, this review proposes protocol standardization, operator training and AI-enabled quantification to advance its clinical application.

Gastric tumors urgently require a simple, inexpensive, noninvasive and easily accessible screening method.Gastric contrast ultrasonography demonstrates utility in detecting and staging gastric tumors.Gastric contrast ultrasonography offers accessible and effective tools for screening of gastric cancer.Accelerating clinical application of gastric contrast ultrasonography demands standardization and technological innovation.

Gastric tumors urgently require a simple, inexpensive, noninvasive and easily accessible screening method.

Gastric contrast ultrasonography demonstrates utility in detecting and staging gastric tumors.

Gastric contrast ultrasonography offers accessible and effective tools for screening of gastric cancer.

Accelerating clinical application of gastric contrast ultrasonography demands standardization and technological innovation.

## Linked entities

- **Diseases:** gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}
- **Diseases:** AT (MESH:D000377), deformity (MESH:D009140), Noncommunicable Chronic Diseases (MESH:D000073296), fibrosis (MESH:D005355), gastric abnormalities (MESH:D013272), Tumor (MESH:D009369), LNM (MESH:D008207), necrosis (MESH:D009336), lymphoma (MESH:D008223), inflammation (MESH:D007249), mucosal lesion (MESH:D009059), GIST (MESH:D046152), ulcer (MESH:D014456), lymph node (MESH:D000072717), flatulence (MESH:D005414), hemorrhage (MESH:D006470), gastric polyps (MESH:D011127), metastasis (MESH:D009362), obese (MESH:D009765), pain (MESH:D010146), T (MESH:D001260), dysplasia (MESH:D015792), AGC (MESH:D013274), MALT (MESH:D018442), gastrointestinal lesions (MESH:D005767), N (MESH:C536108), DLBCL (MESH:D016403), fundic gland polyps (MESH:C566775), OCUS (MESH:D005119), oncologic (MESH:D000072716)
- **Chemicals:** methylcellulose (MESH:D008747), barium (MESH:D001464), water (MESH:D014867), sulfur hexafluoride (MESH:D013459), SonoVue (MESH:C420843), PI (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12996519/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12996519/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12996519/full.md

---
Source: https://tomesphere.com/paper/PMC12996519